Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Approvals Analysis: Original PMA Slowdown, De Novo Upswing Among Recent Trends

Executive Summary

The volume of original PMAs coming to US FDA for review is down recently, while panel-track supplement, de novo and 510(k) volumes are up. October, meanwhile, was a relatively light month for novel device approvals, but better-than-average for 510(k) clearances.

You may also be interested in...



Acutus Is Trying To Fundamentally Change Understanding Of Arrhythmia With AcQMap

New trial results show Acutus Medical's AcQMap platform has the ability to classify conduction patterns and localized non-pulmonary-vein therapeutic targets for ablation to treat atrial fibrillation, which could have implications for both treatment of atrial fibrillation and understanding the genetic markers for this common arrhythmia, according to the authors.

DEVICE DEBUTS: Product And New Indication Launches From Medtronic, Strkyer, Siemens, And More

This month's edition of Device Debuts includes new product launches from Medtronic, Cochlear, Qualcomm, Titan Spine, Stryker, Philips, Nuance, Nevro, Siemens, Vortex BioSciences, ResMed, Respircardia, and others.

'Refuse-To-Accept' Policy Outlined For De Novos In New US FDA Draft Guidance

Following a user fee deal that will subject de novo applications to performance goals and user-fee payments, US FDA has proposed a guidance that attempts to explain its process for considering when to accept, and when not to accept, a de novo submission for review.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT121749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel